Amylyx Pharmaceuticals, Inc. (AMLX) vs Viking Therapeutics, Inc. (VKTX)
A side-by-side comparison of Amylyx Pharmaceuticals, Inc. and Viking Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AMLX
Amylyx Pharmaceuticals, Inc.
$27.75HealthcareDelayed quote: Oct 6, 2026, 3:40 PM EDT
VKTX
Viking Therapeutics, Inc.
$28.39HealthcareDelayed quote: Oct 6, 2026, 3:35 PM EDT
Total return — AMLX vs VKTX
growth of $100 · dividends reinvested · last 5yAMLX +53.7% (+9.0%/yr)VKTX +574.7% (+46.5%/yr)VKTX compounded faster over this window
AMLX VKTX
AMLX vs VKTX: by the numbers
- •VKTX is the larger company ($3.31B vs $3.08B market cap).
Metrics side by side
Valuation
| Metric | AMLX | VKTX |
|---|---|---|
| P/B ratio | 12.90 | 8.11 |
Profitability
| Metric | AMLX | VKTX |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -63.59% | -130.98% |
| ROIC | -66.60% | -135.85% |
Growth (annualized)
| Metric | AMLX | VKTX |
|---|---|---|
| Total return CAGR (5Y) | N/A | 37.36% |
Go deeper
Dig into the metrics
Amylyx Pharmaceuticals ROEViking Therapeutics ROEAmylyx Pharmaceuticals operating marginViking Therapeutics operating marginAmylyx Pharmaceuticals revenue growthViking Therapeutics revenue growthAmylyx Pharmaceuticals free cash flowViking Therapeutics free cash flow
Amylyx Pharmaceuticals & Viking Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.